<DOC>
	<DOCNO>NCT02626754</DOCNO>
	<brief_summary>This multi-national , phase II , single arm study explore safety/efficacy potential biomarkers sunitinib 2/1 schedule Asian patient advance renal cell carcinoma .</brief_summary>
	<brief_title>A Prospective Study Sunitinib First Line Therapy Advanced/Metastatic Renal Cell Carcinoma Asian Population</brief_title>
	<detailed_description>Sunitinib 50mg daily 4/2 dose schedule establish standard care ( SOC ) advance renal cell carcinoma ( RCC ) . However , Asian patient real world experience grade III/IV adverse event much expect . This multi-national , phase II , single arm study go explore safety/efficacy relevant biomarkers sunitinib 2/1 dose schedule Asian people advance RCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Advanced renal cell carcinoma histology confirmation Grade III/IV AEs happen first cycle sunitinib 50mg/day 4 week follow 2 week rest ECOG performance status 0 1 Appropriate vital organ function Prior systemic treatment mRCC Patients treat neoadjuvant adjuvant systemic therapy Major surgery &lt; 4 week radiation therapy &lt; 2 week start study treatment . Prior palliative radiotherapy metastatic lesion ( ) permit , provide least one measurable lesion irradiate Pregnant Allergic history sunitinib</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Sunitinib , 2/1 schedule , Renal cell carcinoma</keyword>
</DOC>